Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Alprostadil in Anterior Non-arteritic Ischemic Optic Neuropathy
NCT03851562Phase 2Unknown
- Sponsor
- Fundación para la Formación e Investigación Sanitaria
- Start
- Jun 2018
- Primary completion
- Jun 2019
- Modality
- Targeted Liposomes, Stealth (PEGylated) Liposomes, Conventional Liposomes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of Alprostadil Liposomes for Injection in anterior ischemic optic neuropathy (AION) (2 arms), sponsored by Fundación para la Formación e Investigación Sanitaria. Primary endpoint: Visual Acuity at 90 days. Status: unknown.
02
Drugs
Alprostadil Liposomes for Injection
03
Conditions
anterior ischemic optic neuropathy (AION)
Beyond the preview
Go deeper on NCT03851562.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03851562.